DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | AliX | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | BioMedical Diagnostics | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-modeling) | BT Pharma | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | Cezanne | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Exonhit | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences (AbAg) | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | Magnisense | Mapreg | MAT Biopharma | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | Novagali | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma (ex-Nova Decision) | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharmaxon | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sepal Pharma | Serial Genetics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UroGene | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* GENTICEL *

 

2001 - Midi-Pyrénées
Labège
(near Toulouse)
www.genticel.com

 

Discovery, Immunology
Key words: Therapeutic vaccines, HPV, Cancer, Viral and bacterial infections, ProCervix
Mission: to develop immuno-therapeutic products for the treatment of infection, neoplasia and cervical cancer, caused by Human Papillomavirus (HPV)
Clients: Prescribers
business@genticel.com

Age: 10 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Timmerman (Ben) [founder, born 1959, Ph.D. Molecular Genetics, MBA, ex-Novartis Agro, Procordia]
Sc.Dir.-CSO: Bissery (Marie-Christine) [Ph.D., Pharm.D., ex-Sanofi–Aventis, Rhône-Poulenc]
Fin.Dir.-CFO: Koch (Martin) [Eng., MBA, ex-Eli Lilly, Cap Gemini, Elan, Zeneus, Cephalon]
BusDev:
Financers (Hist.): Institut Pasteur, FAM-Midi-Pyrénées, Edmond de Rothschild Investment Partners, IRDI, Amundi Private Equity Funds, InnoBio, FSI
Note : from inception to February 2010, the company name has been BT Pharma (BT for Benedikt Timmerman, Founder)

Turnover (M€) : 0.36 (2006)
Total funding (M€) : 24.0
Last funding (M€) : 13.1
Focus : Vaccines
Position : Clinical
Company confirm : 2-May-2011

 

History
DATEMILESTONETYPETIME
2010 .07 Clinical trial (phase I) for Procervix (redesigned) aimed at preventing cervical cancer in patients already infected by HPV (beginning) CLIN [8 years]
2010 .03 3rd round-financing : 13.1 M€, led by AGF Private Equity, with 3 new investors, IRDI (Institut Régional de Développement Industriel), Amundi Private Equity Funds and InnoBio fund, managed by CDC Entreprises, and previous investors, including Edmond de Rothschild Investment Partners (EdRIP) RFINC [8 years]
2010 .02 Company name change from BT Pharma to Genticel INFO [8 years]
2008 .09 2nd round-financing : 2.8 M€ mainly by Edmond de Rothschild Investment Partners, followed by Fonds d'Amorçage Midi-Pyrénées RFINB [6 years]
2007 .09 Clinical trial (phase I) for Procervix, HPV vaccine (beginning) CLIN [5 years]
2007 .05 1st round-financing : 1.3 M€, mainly by Institut Pasteur and an undisclosed private investor RFINA [5 years]
2001 .10 Company founded by Benedikt Timmerman, as a spin-off from Institut Pasteur (Paris) ORGF [0 year]

Actualisation / Updating: 27-Sep-2011

   

Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2011. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende